REG - Scancell Hlds - Scancell to present three posters at ICI

Scancell HoldingsAnnouncement

14/09/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230914:nRSN3786Ma&default-theme=true

RNS Number : 3786M  Scancell Holdings Plc  14 September 2023

14 September 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Scancell to present three posters at the Seventh International Cancer
Immunotherapy Conference

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, announces it will present
three posters at the Seventh International Cancer Immunotherapy Conference
(https://www.cancerimmunotherapyconference.org/) , jointly organised by the
American Association for Cancer Research, the European Network for Cancer
Immunotherapy and the Cancer Research Institute and taking place on 20-23
September 2023 in Milan, Italy.

 

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of
Scancell, commented: "We look forward to presenting at such a prestigious
meeting and sharing data on our preclinical programmes with the scientific
community. As previously disclosed in a recent business update
(https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/230710_scancell-pipeline-strategy-and-business-update_final.pdf)
, we continue to make great progress in the clinic with our two lead cancer
vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical
trials as well as leveraging the value of our antibody platform to generate
revenue through high value licence agreements.

 

"Showcasing the potential of our technology platforms to generate further
pipeline assets with high value partnering opportunities, we will be
presenting encouraging data on both the Moditope® and GlyMab® platforms.
Data on antibody candidates derived from the GlyMab® platform illustrate the
potential of these assets as chimeric antigen receptor T cell (CAR-T)
therapies and could lead to out licensing opportunities with cell therapy
companies. Furthermore, we will be presenting data bolstering the potential of
Modi-2 as a solid tumour cancer therapy and further characterising the
response to Moditope® peptides in preclinical studies."

 

The title, timing and location of the poster presentation are as follows:

 

Poster 1

 

 Poster presentation title  Anti-sialyl-di-lewisa CAR T cells for effective anti-tumour therapy
 Authors                    Iniobong Charles, Katherine Cook, Bubacarr Kaira, Gaëlle Cane, Anne Skinner,
                            Alissa Wright, Mireille Vankemmelbeke, Rachael Metheringham, Victoria
                            Brentville and Lindy Durrant
 Session title              Poster Session A
 Session date and time      12.30 - 14.00 CET, 21(st) September, 2023
 Location                   Poster Board number P232

 

 

Poster 2

 

 Poster presentation title  Vaccination stimulating post-translational modification specific Th1 responses
                            repolarises the tumour environment to reduce suppressive LAP expressing T
                            cells
 Authors                    Suha Atabani, Katherine Cook, Peter Symonds, Ian Daniels, Ruhul Choudhury,
                            Alissa Wright, Anne Skinner, Victoria Brentville and Lindy Durrant
 Session title              Poster Session A
 Session date and time      12.30 - 14.00 CET, 21(st) September, 2023
 Location                   Poster Board number P230

 

 

Poster 3

 

 Poster presentation title  Modi-2, a vaccine targeting homocitrullinated self-epitopes, stimulates potent
                            CD4-mediated anti-tumour responses as a therapy for solid cancers
 Authors                    Abdullah Al-Omari, Katherine Cook, Peter Symonds, Anne Skinner, Yaling Zhu,
                            Vince Coble, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally Adams,
                            Geoffrey Lynn, Lindy Durrant and Victoria Brentville
 Session title              Poster Session B
 Session date and time      12.45 - 14.00 CET, 22(nd) September, 2023
 Location                   Poster Board number P217

 

 

Copies of the poster will be available on Scancell's website following the
conference at: https://www.scancell.co.uk/vaccine-publications
(https://www.scancell.co.uk/vaccine-publications)

 

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3727 1000
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications                                           Tel.: +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFIFUDEDSEIU